Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Efficacy of IAP0971 in Advanced Tumors
NCT06581419Phase 2Recruiting
- Sponsor
- SUNHO BioPharmaceutical
- Start
- Dec 2024
- Primary completion
- Aug 2029
- Modality
- Immunomodulatory ADCs, Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 2, open-label trial of IAP0971 in advanced malignant solid tumor and non-small cell lung cancer (NSCLC) (2 arms), sponsored by SUNHO BioPharmaceutical. Primary endpoints: Frequency of Adverse Events (AEs) and Serious Adverse Events (SAEs), Dose Limiting Toxicities and 1 more. Started Dec 2024; status: recruiting.
02
Drugs
IAP0971
03
Conditions
advanced malignant solid tumornon-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06581419.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06581419.